title: Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers.
abstract: Gemifloxacin is a novel fluoroquinolone with a broad spectrum of antibacterial activity. The objective of this double-blind, randomized, placebo-controlled, 2-way crossover study was to demonstrate the lack of a pharmacokinetic interaction between gemifloxacin and digoxin. During two 14-day treatment periods, healthy elderly volunteers received digoxin (0.25 mg, once daily) co-administered on days 8-14 with either gemifloxacin (320 mg, p.o., once daily) or placebo. On day 14 of each period, blood samples and urine were collected for 24 h post dose and analysed for digoxin levels by radioimmunoassay. Steady-state digoxin pharmacokinetics were not affected by multiple dosing with gemifloxacin. There was no significant difference in digoxin values for the area under the plasma concentration-time curve over the dosing interval 0-24 h (AUC((0-24))) or the trough plasma concentration (C24) after co-administration with either gemifloxacin or placebo. Geometric means for AUC((0-24)) and C24 were 18.1 and 17.8 ng x h/ml and 0.597 and 0.566 ng/ml, respectively. The point estimates (90% confidence intervals) for AUC((0-24)) and C24 (digoxin + gemifloxacin):(digoxin + placebo) were 1.01 (0.93, 1.10) and 1.05 (0.95, 1.16), respectively, entirely within the equivalence range (0.80, 1.25). There were no marked differences between co-administration regimens for maximum observed plasma concentration (C(max)) or renal clearance values. Gemifloxacin was well tolerated during co-administration with digoxin, and the incidence of adverse events was similar to that seen with placebo. There were no clinically relevant changes in vital signs, electrocardiogram readings or laboratory parameters. In conclusion, this study demonstrates that gemifloxacin may be co-administered with digoxin without the need for digoxin dose adjustment.
authors.affiliation: Clinical Pharmacology Department, SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK. Marika_Vousden-1@sbphrd.com
authors.forename: M
authors.initials: M
authors.lastname: Vousden
authors.forename: A
authors.initials: A
authors.lastname: Allen
authors.forename: A
authors.initials: A
authors.lastname: Lewis
authors.forename: N
authors.initials: N
authors.lastname: Ehren
mesh_terms: D000368:Aged; D000890:Anti-Infective Agents / Q000494:pharmacology*; D018592:Cross-Over Studies; D004077:Digoxin / Q000493:pharmacokinetics*; D004311:Double-Blind Method; D004347:Drug Interactions; D005260:Female; D024841:Fluoroquinolones; D000077735:Gemifloxacin; D006801:Humans; D008297:Male; D008875:Middle Aged; D009287:Naphthyridines / Q000494:pharmacology*
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D004077:Digoxin; D000077735:Gemifloxacin